Cancer results from failures in epigenetic control by chromatin remodelers at the level of gene transcription. The abnormal activation of epithelial to mesenchymal transition (EMT) by carcinomas is an essential hallmark of cancer metastasis that is responsible for more than 90% of cancer deaths.

Our aim is to elucidate the orchestration of EMT-MET cascade by the balancing act of chromatin remodelers and epigenetic modifiers. It is anticipated that chromatin modifying compounds will emerge as the next generation of anticancer therapies.